Skip To Main Content
Natalia Baran on Muck Rack

Natalia Baran

As seen in: Nature, Frontiers, MDPI, BioRxiv, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Natalia

Contact Natalia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function - Oncogene

|
By Vivek Anand, Natalia Baran, Stephen Wong, Michael Andreeff
| Nature Verified
Abstract TP53 mutations are common in breast cancer (BC) and are associated with poor prognosis. GD3 synthase (GD3S/ST8SIA1), a gene associated with breast cancer stem cells, is upregulated in tumors with p53 mutations. However, the functional relationship between GD3S and p53 is unknown. Here, we show that GD3S levels are highest in breast tumors with specific p53 mutations.
Open in Who Shared Issue with article?

Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications

|
By Shaimaa S. Khattab, Adriatik Berisha, Natalia Baran
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses - Nature Cancer

|
By Courtney DiNardo, Divij Verma, Natalia Baran, Tianyu Cai, Veronica Guerra, Gowri Poigaialwar, Meghan Collins, Michael Green, Gautam Borthakur, Elias Jabbour, Tapan M Kadia, Steven Kornblau, Guillermo Garcia-Manero, Stefano Tiziani
| Nature Verified
Abstract Malignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective glutaminase inhibitor, combined with azacytidine (AZA), followed by a single-arm, open-label, phase 1b/2 study in persons with advanced myelodysplastic syndrome (MDS).
Open in Who Shared Issue with article?
See all 17 articles